333361-68-5Relevant academic research and scientific papers
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Meng, Wei,Ellsworth, Bruce A.,Nirschl, Alexandra A.,McCann, Peggy J.,Patel, Manorama,Girotra, Ravindar N.,Wu, Gang,Sher, Philip M.,Morrison, Eamonn P.,Biller, Scott A.,Zahler, Robert,Deshpande, Prashant P.,Pullockaran, Annie,Hagan, Deborah L.,Morgan, Nathan,Taylor, Joseph R.,Obermeier, Mary T.,Humphreys, William G.,Khanna, Ashish,Discenza, Lorell,Robertson, James G.,Wang, Aiying,Han, Songping,Wetterau, John R.,Janovitz, Evan B.,Flint, Oliver P.,Whaley, Jean M.,Washburn, William N.
, p. 1145 - 1149 (2008/09/20)
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
